Enabling Patient Foundations to Build the Next Generation of Genetic Therapies

Katharina, thanks for joining us.

Thank you so much.

We're going to talk about non-muscle invasive bladder cancer, Hamlet Biopharma, and your efforts to develop a new class of therapies based on components of human breast milk.

Bladder cancer and serious urinary infections are common, yet many patients still run out of good options.

Where are the biggest gaps in today's treatments for non-muscle invasive bladder cancer and hard-to-treat urinary tract infections?

Thank you for this question.

Yes, we have developed new therapies for two important clinical areas, one being cancer and the second bacterial infections.

This has been achieved by combining hardcore basic science with clinical development into the drug arena by our group of people who actually are both scientists and entrepreneurs.

And it's quite exciting.

We discovered new molecules and we then take them to the clinic.

We have achieved this for three phase two studies and are going ahead with the next phases.

So the new cancer-killing molecule is Hamlet, the one that we found in breast milk.

And it has amazing properties in terms of its anti-cancer activity.

It kills many different types of cancer cell lines in the lab.

It's active in animal models against cancer.

And it has a conserved mechanism that explains this broad activity.

It's also selective.

There is very little in terms of side effects and no killing of healthy tissue.

In terms of the infection approach, instead of killing the bacteria with antibiotics, we are actually trying to stop the disease, the patient.

So we identify the patient responsible for the disease and turn it off with our new molecules.

And this makes it possible to treat infections caused by both antibiotic resistant and antibiotic sensitive bacteria.